265 related articles for article (PubMed ID: 34493145)
1. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
[TBL] [Abstract][Full Text] [Related]
3. Luspatercept for β-thalassemia: beyond red blood cell transfusions.
Taher AT; Cappellini MD
Expert Opin Biol Ther; 2021 Nov; 21(11):1363-1371. PubMed ID: 34404288
[TBL] [Abstract][Full Text] [Related]
4. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
6. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.
Kansal AR; Reifsnider OS; Brand SB; Hawkins N; Coughlan A; Li S; Cragin L; Paramore C; Dietz AC; Caro JJ
J Mark Access Health Policy; 2021 Jun; 9(1):1922028. PubMed ID: 34178295
[No Abstract] [Full Text] [Related]
8. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
[TBL] [Abstract][Full Text] [Related]
10. Cell-Based Gene Therapy for b-Thalassemia.
Arya Y; Sahi PK
Indian Pediatr; 2023 Apr; 60(4):313-316. PubMed ID: 37002845
[TBL] [Abstract][Full Text] [Related]
11. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
[TBL] [Abstract][Full Text] [Related]
12. Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience.
Pinto VM; Poggi M; Russo R; Giusti A; Forni GL
Blood Rev; 2019 Nov; 38():100594. PubMed ID: 31416718
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Cappellini MD; Taher AT; Piga A; Shah F; Voskaridou E; Viprakasit V; Porter JB; Hermine O; Neufeld EJ; Thompson AA; Tang D; Yucel A; Lord-Bessen J; Yu P; Guo S; Shetty JK; Miteva D; Zinger T; Backstrom JT; Oliva EN
Eur J Haematol; 2023 Jul; 111(1):113-124. PubMed ID: 37095595
[TBL] [Abstract][Full Text] [Related]
14. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
[TBL] [Abstract][Full Text] [Related]
15. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease.
Ferraresi M; Panzieri DL; Leoni S; Cappellini MD; Kattamis A; Motta I
Eur J Pediatr; 2023 Jun; 182(6):2509-2519. PubMed ID: 36997768
[TBL] [Abstract][Full Text] [Related]
17. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
18. Challenges in chronic transfusion for patients with thalassemia.
Lal A
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):160-166. PubMed ID: 33275743
[TBL] [Abstract][Full Text] [Related]
19. Thalassemia in Indonesia.
Wahidiyat PA; Sari TT; Rahmartani LD; Iskandar SD; Pratanata AM; Yapiy I; Setianingsih I; Atmakusuma TD; Lubis AM
Hemoglobin; 2022 Jan; 46(1):39-44. PubMed ID: 35950580
[TBL] [Abstract][Full Text] [Related]
20. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.
Betts M; Flight PA; Paramore LC; Tian L; Milenković D; Sheth S
Clin Ther; 2020 Feb; 42(2):322-337.e2. PubMed ID: 31882227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
